Heart Failure
March 9, 2026
Barostim Boosts QoL and LVEF, but Mortality Benefit Still Unknown March 9, 2026
Strong results from two separate studies on CVRx’s Barostim baroreflex activation therapy suggest the technology might offer symptomatic relief even though its mortality benefit is still up in the air. The first of two Barostim studies discussed at THT 2026, the REBALANCE registry enrolled 435 patients with a low average baseline LVEF, mostly NYHA class […]
Cardiology Testing
March 5, 2026
What NT-proBNP Can Tell Us About TEER Outcomes March 5, 2026
New research presented at THT 2026 suggests that the NT-proBNP biomarker could give us a glimpse into which patients with severe tricuspid regurgitation (TR) will benefit the most from transcatheter edge-to-edge repair (TEER). Using data from the EuroTR registry, researchers evaluated 2.2k patients undergoing TEER, and organized them into three NT-proBNP categories (≤1,674, 1,675-3,743, >3,743 […]
Cardiology Testing
March 2, 2026
Two Cardiac Troponins Don’t Tell the Same Story March 2, 2026
There might be a bigger difference between the types of cardiac troponin assays, after a recent JACC analysis found that the type of troponin could help us better understand the kind of damage occurring after a heart attack. As part of a multicohort validation, researchers examined 9.7k patients who were marked as having no known, […]
